COMBS ANDREW (EVP, Head of Chemistry) purchased 26.3% of their position (100K shares) of PRELUDE THERAPEUTICS INC on the open market
Open‑market purchase worth $69.3K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 3/27/2025ACC: 0001562180-25-002779
Officer· EVP, Head of Chemistry
Since Sep 2020
+100K
Net shares
Net buyer
$69.3K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
100K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+100K
Price / share
$0.69
Trade value
$69.25K
% of position
26.3%
3/25/2025
380.12K→480.12K
Total
Net shares
+100K
Net value
$69.25K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/25/2025 | P · Purchase | +100K | $0.69 | $69.25K | 26.3% | 380.12K | 480.12K |
| Total | +100K | $69.25K | ||||||
Derivative Transactions0
No derivative transactions reported